Detalhe da pesquisa
1.
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
N Engl J Med
; 381(24): 2315-2326, 2019 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826340
2.
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Br J Cancer
; 125(5): 687-698, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34140638
3.
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Blood
; 134(23): 2036-2045, 2019 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31511239
4.
Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects.
Xenobiotica
; 50(2): 150-169, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31006307
5.
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
Haematologica
; 101(2): 226-34, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26659915
6.
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
Br J Clin Pharmacol
; 80(5): 1001-9, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25900065
7.
Relative Bioavailability and Food Effect of Asciminib Pediatric Mini-tablet Formulation Compared to the Reference Tablet Formulation in Healthy Adult Participants.
Clin Pharmacol Drug Dev
; 12(5): 484-492, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36622274
8.
Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants.
Clin Transl Sci
; 15(6): 1406-1416, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293131
9.
Pharmacokinetics of Asciminib When Taken With Imatinib or With Food.
Clin Pharmacol Drug Dev
; 11(2): 207-219, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34609077
10.
Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents.
Clin Transl Sci
; 15(7): 1698-1712, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35616006
11.
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
J Clin Pharmacol
; 61(11): 1454-1465, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34115385
12.
Physiologically Based Pharmacokinetic Modeling to Supplement Nilotinib Pharmacokinetics and Confirm Dose Selection in Pediatric Patients.
J Pharm Sci
; 108(6): 2191-2198, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30721710
13.
Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor.
J Clin Pharmacol
; 58(12): 1533-1540, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30179260
14.
Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.
J Clin Oncol
; 32(17): 1782-91, 2014 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24821885